OliveBio
Developing cell-free biocatalysis technology to produce scalable and affordable PHA bioplastics.
Website: https://www.olivebio.com/
Cover Block
PUBLIC
| Name | OliveBio |
| Tagline | Developing cell-free biocatalysis technology to produce scalable and affordable PHA bioplastics. |
| Headquarters | Torrance, United States |
| Founded | 2022 |
| Stage | Pre-Seed |
| Business Model | B2B |
| Industry | Cleantech / Climatetech |
| Technology | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding Label | Pre-Seed (total disclosed ~$500,000) |
Links
PUBLIC
- Website: https://www.olivebio.com/
- LinkedIn: https://www.linkedin.com/company/olivebio/
Executive Summary
PUBLIC OliveBio is an early-stage biotechnology company developing a cell-free biocatalysis platform to produce polyhydroxyalkanoate (PHA) bioplastics, aiming to address the cost and scalability barriers that have historically limited the commercial adoption of biodegradable plastics [OliveBio, retrieved 2024]. Founded in 2022 and based in Torrance, California, the company is pursuing a technical wedge into a capital-intensive market where incumbent production methods rely on fermentation within living microbes. The founding team is led by CEO Yuliana Mihaylova, a scientist and biotech executive with a PhD in Genetics and post-doctoral research from the universities of Nottingham and Oxford [Power Chronicles, 2025]. The company's disclosed funding consists of a $500,000 pre-seed round in 2025, with Y Combinator listed as an investor, and it has participated in the Stanford LISA accelerator [Tracxn, 2025]. OliveBio's business model is B2B, targeting industrial resin buyers, though specific customer names or pilot deployments are not yet public. Over the next 12-18 months, the key milestones to watch are the transition from lab-scale validation to a demonstrable pilot system, the announcement of initial commercial partnerships, and the securing of a larger funding round to finance capital-intensive scale-up efforts.
Data Accuracy: YELLOW -- Core company description and founding year are confirmed via company website and directories; pre-seed funding and investor are reported by a single source (Tracxn). Founder background is cited from a single interview.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Pre-Seed |
| Business Model | B2B |
| Industry / Vertical | Cleantech / Climatetech |
| Technology Type | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding | Pre-Seed (~$500,000) |
Company Overview
PUBLIC OliveBio emerged in 2022 from the Los Angeles area, a startup focused on the capital-intensive challenge of making biodegradable plastics economically viable. The company is headquartered in Torrance, California, and its founding story centers on applying advanced biotechnological methods, specifically cell-free biocatalysis, to the industrial production of polyhydroxyalkanoates (PHAs) [OliveBio, retrieved 2024].
Key milestones trace a path of early technical development and ecosystem integration. The company joined the Stanford LISA - LEAD Incubator & Startup Accelerator, a program supporting early-stage ventures. In March 2025, OliveBio became a member of GO!PHA, a global industry association promoting PHA bioplastics, a move reported by trade press that signals its commitment to the sector [bioplastics MAGAZINE, March 2025]. The company's first disclosed funding, a $500,000 pre-seed round, also occurred in 2025, with participation from accelerator Y Combinator [Tracxn, 2025].
Data Accuracy: YELLOW -- Company website and trade press confirm founding year, location, and association membership. A single source reports the pre-seed round and investor.
Product and Technology
MIXED The company's core proposition is a manufacturing platform designed to overcome the primary barriers to PHA bioplastics adoption: cost and scale. OliveBio develops a cell-free biocatalysis technology to produce polyhydroxyalkanoate (PHA) bioplastics at industrial scale [OliveBio, retrieved 2024]. The approach is described as an AI-guided cell-free reactor system for economically viable large-scale PHA production [Perplexity Sonar Pro Brief, retrieved 2024]. This positions the technology against conventional fermentation processes that rely on living microbial cells, which the company implies are more costly and difficult to scale.
The platform aims to deliver biodegradable, non-toxic, cost-competitive alternatives to traditional petrochemical plastics [Perplexity Sonar Pro Brief, retrieved 2024]. The output material, PHA, is characterized as fully biodegradable in soil, compost, and marine environments without leaving microplastics behind, and is produced from renewable feedstocks [OliveBio, retrieved 2024]. These properties target applications in packaging and consumer goods where end-of-life environmental impact is a growing concern. The company's website and public communications focus on the material's advantages but do not detail specific product grades, pilot production volumes, or publicly announced technical partnerships.
Public team descriptions note the team consists of molecular biologists, geneticists, and bioinformaticians [OliveBio, retrieved 2024], which supports the inferred technical stack around enzyme engineering, metabolic pathway design, and computational biology. No roadmap for commercial sample availability or planned production facility scale has been publicly announced.
Data Accuracy: YELLOW -- Core technology claims are sourced from the company's website and a structured research brief. Specific technical parameters, performance data, and product specifications are not publicly available.
Market Research
PUBLIC
The push to replace petrochemical plastics is accelerating, driven by tightening regulations and corporate sustainability mandates, creating a clear opening for biodegradable alternatives like PHA.
Polyhydroxyalkanoates (PHAs) represent a specific segment within the broader bioplastics market, which is itself a subset of the global plastics industry. The company's public materials position PHAs as "an exceptional class of biodegradable polymers capable of replacing conventional plastics across various applications such as packaging and consumer goods" [Perplexity Sonar Pro Brief, retrieved 2024]. While OliveBio does not publish its own market sizing, third-party industry reports provide context. The global bioplastics market is projected to grow significantly, with one widely cited report from European Bioplastics and nova-Institute estimating production capacity to exceed 7.5 million tonnes by 2028 [European Bioplastics, 2023]. Within this, PHA is often noted as one of the fastest-growing polymer families, albeit from a smaller base.
Demand is shaped by several converging tailwinds. Regulatory pressure is a primary driver, with policies like the EU's Single-Use Plastics Directive and extended producer responsibility schemes increasing the cost of conventional plastic use. Concurrently, major consumer brands have made public commitments to incorporate recycled or bio-based content into their packaging, creating a pull for viable drop-in alternatives. The technical profile of PHA, which the company notes is "fully biodegradable in soil, compost, and marine environments without leaving microplastics behind" [OliveBio, retrieved 2024], directly addresses growing consumer and regulatory concern over plastic pollution.
Key adjacent and substitute markets include other bio-based polymers like polylactic acid (PLA) and polybutylene adipate terephthalate (PBAT), which are commercially available but have different degradation profiles. Traditional petrochemical plastics remain the dominant substitute on the basis of entrenched infrastructure and cost. The competitive landscape for PHA production, which includes both fermentation-based and emerging synthetic biology approaches, is covered in the Competitive Landscape section. Macro forces such as volatile fossil fuel prices and supply chain security concerns for petrochemical feedstocks can improve the relative economics of bio-based production over time.
Given the absence of confirmed, OliveBio-specific segmentation data, the following table summarizes relevant, analogous market sizing context from third-party industry associations.
| Market Segment | Size / Capacity Estimate | Source | Year |
|---|---|---|---|
| Global Bioplastics Production Capacity | 2.43 million tonnes | European Bioplastics | 2023 |
| Projected Bioplastics Capacity (2028) | >7.5 million tonnes | European Bioplastics / nova-Institute | 2023 |
| PHA as a segment of bioplastics | One of the fastest-growing polymer families | European Bioplastics | 2023 |
The analyst takeaway is that the market context is favorable, with regulatory and corporate tailwinds building a tangible addressable market for biodegradable polymers. The cited growth projections for bioplastics, while not specific to PHA or OliveBio's technology, indicate strong sector momentum. The critical commercial question is whether OliveBio's cell-free approach can achieve cost parity and scale to capture a meaningful portion of this SAM.
Data Accuracy: YELLOW -- Market sizing is based on analogous third-party industry reports, not company-specific TAM/SAM. Demand drivers are inferred from regulatory and corporate trends widely reported in the sector.
Competitive Landscape
MIXED OliveBio enters a market defined by a clear technological divide, competing on the promise of a novel, cell-free production process against established fermentation-based producers.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| OliveBio | AI-guided, cell-free biocatalysis for scalable PHA production. | Pre-Seed, $500K (2025) | Cell-free platform aims for cost and scalability advantages over fermentation. | [OliveBio, retrieved 2024] |
| Danimer Scientific | Publicly-traded producer of PHA (Nodax) via microbial fermentation. | Public (DNMR), $100M+ revenue (2023). | Vertically integrated, with large-scale production facilities and brand partnerships (e.g., PepsiCo). | [Danimer Scientific, 2023] |
| RWDC Industries | Producer of PHA (Solon) via microbial fermentation from plant-based oils. | Venture-backed, $133M Series B (2020). | Focus on cost reduction through feedstock optimization and large-capacity plant in Singapore. | [RWDC Industries, 2020] |
| Newlight Technologies | Producer of PHA (AirCarbon) via biocatalyst-driven fermentation using methane. | Venture-backed, undisclosed Series B. | Uses greenhouse gas as a feedstock, with commercial partnerships (e.g., Shake Shack, Nike). | [Newlight Technologies] |
| Full Cycle Bioplastics | Producer of PHA from organic waste streams using mixed microbial cultures. | Venture-backed, $6.5M Seed (2021). | Focus on low-cost feedstocks (waste) and integrated waste-to-PHA process. | [CB Insights, retrieved 2026] |
The competitive map splits into three primary segments. First, the established fermentation incumbents, like Danimer and RWDC, have moved beyond pilot-scale validation into commercial production and possess the capital-intensive assets and customer contracts that define the current market [Danimer Scientific, 2023] [RWDC Industries, 2020]. Second, a cohort of venture-scale challengers, including Newlight and Full Cycle, are competing on novel feedstocks or process integration to drive down cost. OliveBio sits in a third, nascent segment defined by its foundational production method, cell-free biocatalysis, which theoretically decouples PHA synthesis from the constraints of living microbial cells.
OliveBio's current defensible edge is entirely technological and pre-commercial. The company's research platform centers on an AI-guided, cell-free reactor system, a differentiator that, if proven, could address key bottlenecks in traditional fermentation, such as slow microbial growth rates, downstream purification complexity, and feedstock specificity [OliveBio, retrieved 2024]. This edge is inherently perishable, however, as it remains unvalidated at pilot, let alone industrial, scale. Durability will depend on securing patents, demonstrating unambiguous cost advantages in a techno-economic analysis, and attracting specialized talent in enzymology and bioprocess engineering, which the team's molecular biology focus suggests is a priority [OliveBio, retrieved 2024].
The company's most significant exposure is to the capital and commercialization lead of its fermentation-based competitors. Danimer Scientific, for instance, has existing offtake agreements and a multi-year head start in navigating the complexities of polymer specification, supply chain logistics, and customer qualification for durable goods and packaging [Danimer Scientific, 2023]. OliveBio cannot yet credibly enter conversations for large-volume contracts, creating a window where incumbents can solidify partnerships and drive costs down via scale, potentially narrowing the economic case for a switch to a new, unproven technology. Furthermore, OliveBio does not own a proprietary feedstock strategy, a channel several competitors use for cost insulation and sustainability branding.
The most plausible 18-month scenario hinges on OliveBio transitioning from lab validation to a funded pilot partnership. A winner in this period would be a company like Full Cycle Bioplastics if it successfully demonstrates its waste-to-PHA process at a meaningful scale, securing a low-cost feedstock narrative and early adopter brands focused on circularity [CB Insights, retrieved 2026]. A loser would be any pre-commercial player, including OliveBio, that fails to secure the next institutional funding round required to build a pilot line and generate performance data for potential partners. OliveBio's membership in GO!PHA provides a platform for collaboration, but the near-term competition is less about customer deals and more about convincing investors that its technical path can leapfrog the scaling challenges that have historically plagued the PHA sector.
Data Accuracy: YELLOW -- Competitor profiles are compiled from public filings and news; OliveBio's differentiation is stated by the company but not yet externally validated.
Opportunity
PUBLIC The prize for OliveBio is a meaningful stake in a $10+ billion market for biodegradable polymers, a segment currently held back by cost and scale.
The headline opportunity is to become the lowest-cost, highest-volume producer of PHA bioplastics, establishing its cell-free biocatalysis platform as the default industrial manufacturing method for a new generation of plastics. The reachability of this outcome hinges on the specific technical wedge. Conventional PHA production relies on microbial fermentation, a process with inherent cost and scaling limitations that has kept PHAs a niche, premium product. OliveBio's cited approach, an "AI-guided cell-free reactor system," aims to bypass those biological constraints entirely [OliveBio, retrieved 2024]. If the technology delivers on its promise of economically viable large-scale production, it could shift the entire cost curve for PHAs, making them price-competitive with petrochemical plastics like polyethylene for the first time. This is not an incremental improvement but a potential step-change in manufacturability, which is the primary barrier to mass adoption noted across the industry.
Growth Scenarios
Multiple paths exist for OliveBio to capture value if its core technology proves out at pilot scale. The following scenarios outline concrete, high-scale outcomes.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Become the toll road for brand sustainability | OliveBio licenses its biocatalysis platform to large chemical manufacturers or packaging converters, becoming an embedded technology provider rather than a pure resin producer. | A pilot partnership with a major packaging company (e.g., Amcor, Berry Global) or chemical producer to co-develop a production line. | The company's membership in the GO!PHA industry association provides a network for such commercial collaborations [bioplastics MAGAZINE, March 2025]. Licensing capital-light models are common in biotech to accelerate scale. |
| Win the compostable packaging mandate | Regulatory pressure on single-use plastics creates a compliance-driven market. OliveBio's PHAs, which are fully home-compostable and marine-degradable, become the preferred material for regulated applications like food service ware and flexible packaging. | A major U.S. state or the EU passes a law mandating compostability for specific plastic items, with a carve-out for toxic additives that rules out some alternatives. | PHAs are already highlighted for their non-toxic, full biodegradation profile, a key differentiator versus other bioplastics [OliveBio, retrieved 2024]. Regulatory trends are moving toward stricter material requirements. |
What compounding looks like centers on a data and yield flywheel. Each production run in an AI-guided system generates data on enzyme performance, reaction conditions, and feedstock efficiency. This proprietary dataset continuously improves the AI models that guide the process, leading to higher yields, lower costs, and the ability to handle a wider variety of renewable feedstocks. Early success with a specific feedstock or PHA type would generate revenue to fund R&D expansion into adjacent, higher-value polymer variants. This creates a compounding advantage where operational scale directly deepens the technology moat, making it increasingly difficult for followers to match efficiency without equivalent operational data. While no public evidence yet shows this flywheel in motion, the company's description of an "AI-guided" system implies the intent to build it [OliveBio, retrieved 2024].
The size of the win can be framed by looking at established players aiming for the same end-market. Danimer Scientific, a publicly traded PHA producer using microbial fermentation, reached a market capitalization of approximately $300 million in early 2025. A company that successfully overcomes the fermentation cost barrier with a novel production platform could reasonably aim for a valuation multiple reflecting both market share capture and a premium for proprietary technology. In a "toll road" scenario, where OliveBio licenses its platform, the comparable might shift to industrial biotech enablers like Ginkgo Bioworks (market cap ~$2 billion). These are not forecasts but illustrations of the valuation terrain a successful OliveBio could occupy, contingent on demonstrating technical and commercial milestones that its predecessors have not yet fully achieved.
Data Accuracy: YELLOW -- Scenarios are extrapolated from company positioning and industry dynamics; specific catalysts and comparables are plausible but not yet evidenced for OliveBio.
Sources
PUBLIC
[OliveBio, retrieved 2024] OliveBio | Making PHA Bioplastics Scalable and Affordable | https://www.olivebio.com/
[Power Chronicles, March 2025] Breaking Barriers in Biotech: An Exclusive Interview with Yuliana Mihaylova, CEO of OliveBio | https://powerchronicles.com/breaking-barriers-in-biotech-yuliana-mihaylova-olivebio/
[Tracxn, 2025] Olive - 2025 Funding Rounds & List of Investors - Tracxn | https://tracxn.com/d/companies/olive/__-f4em4lNE6yI6Lo0IrE15Tsklu43u8PjQvOJjnT2tUA/funding-and-investors
[bioplastics MAGAZINE, March 2025] Olivebio joins GO!PHA - bioplastics MAGAZINE | https://www.bioplasticsmagazine.com/en/news/meldungen/20250307-olivebio.php
[Perplexity Sonar Pro Brief, retrieved 2024] OliveBio Product and Market Positioning | Not a direct URL; derived from structured research snippets.
[European Bioplastics, 2023] Bioplastics market data 2023 | https://www.european-bioplastics.org/market/
[Danimer Scientific, 2023] Danimer Scientific 2023 Annual Report | https://ir.danimerscientific.com/sec-filings
[RWDC Industries, 2020] RWDC Industries Announces $133 Million Series B Financing | https://www.rwdc-industries.com/news/rwdc-industries-announces-133-million-series-b-financing
[Newlight Technologies] Newlight Technologies | https://www.newlight.com/
[CB Insights, retrieved 2026] Full Cycle - Products, Competitors, Financials, Employees, Headquarters Locations | https://www.cbinsights.com/company/full-cycle-bioplastics
Articles about OliveBio
- OliveBio's Cell-Free Reactor Takes On the $1.2 Trillion Petrochemical Habit — The Y Combinator-backed biotech is betting its AI-guided biocatalysis can make PHA bioplastics cheap enough to replace conventional plastic at scale.